FlagInternationalUnited States
 

Overview

Corporate Profile

Uroplasty, Inc. is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices.

Uroplasty products are typically used when a patient’s treatment goals are not met after conservative and/or drug therapies. Providers and patients alike appreciate that Uroplasty products provide low-risk, effective alternatives to invasive surgery. And because these treatments can be delivered in an office or outpatient setting, the end result is that more patients are given the opportunity to transform their lives with successful treatment.

 
Stock Quote
UPI (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$3.37
Change (%) Stock is Up 0.11 (3.37%)
Volume25,661
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
04/17/14Uroplasty Names Daniel P. Merz As Vice President Of Healthcare Affairs
MINNEAPOLIS, April 17, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced  that Daniel P. Merz has joined the Company as Vice President of Healthcare Affairs. In this role, he will oversee Uroplasty's strategy to educate payors and providers of the efficiency, effectiveness and overall value of the Company's products.  He joins Uroplasty wit... 
 Printer Friendly Version
02/26/14Uroplasty To Participate In The ROTH 26th Annual Conference
MINNEAPOLIS, Feb. 26, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz Carlton in Laguna... 
 Printer Friendly Version
02/06/14Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Independence Blue Cross
~Positive Coverage Decision Adds 2.2 Million Covered Lives for Up to Two Years of Treatment with Urgent PC MINNEAPOLIS, Feb. 6, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Independence Blue Cross (IBC) has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty... 
 Printer Friendly Version
01/27/14Uroplasty Appoints Suranjan Roychowdhury, Ph.D. to New Vice President of Research & Development and Clinical Affairs Role
Experienced Executive in Development and Commercialization of Medical Devices to Assume Key New Position MINNEAPOLIS, Jan. 27, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it has appointed Dr. Suranjan Roychowdhury as Vice President of Research & Development and Clinical Affairs. This newly created position within the Uro... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Uroplasty, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.